Boehringer Ingelheim Acquires Northern Biologics ’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio Acquisition provides assets targeting the tumor stroma and myeloid cellsThese new programs targeting the tumor microenvironment are the latest in a series of strategic acquisitions and collaborations that strengthen Boehringer Ingelheim ’s position in cancer immunology, with leading assets and robust capabilities in cancer vaccines, oncolytic viruses,  T-cell engagers and myeloid cell modulators Acquisition of Versant-built company based in Toronto ’s MaRS Discovery District
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news